Associated Papers
Impaired nuclear PTEN function drives macrocephaly, lymphadenopathy and late-onset cancer in PTEN hamartoma tumour syndrome.
Tibarewal P et al.
Disease Models & Mechanisms, 2026
Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers.
Langdon CG
Biomolecules, 2023
Molecular dynamic simulation and functional analysis of pathogenic PTEN mutations in glioblastoma.
Cetintas VB et al.
Journal of Biomolecular Structure & Dynamics, 2023
PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
Ferdosi SR et al.
Neuro-oncology, 2022
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Day EK et al.
Cancer Research, 2021
The Impact of Genetic Variants on PTEN Molecular Functions and Cellular Phenotypes.
Hasle N et al.
Cold Spring Harbor Perspectives in Medicine, 2019
Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.
Ma J et al.
Cancer Cell, 2019
Multiplex assessment of protein variant abundance by massively parallel sequencing.
Matreyek KA et al.
Nature Genetics, 2018
29785012 (PubMed )
Supplement: NIHMS956040-supplement-2.doc
Therapeutic targeting of cancers with loss of PTEN function.
Dillon LM et al.
Current Drug Targets, 2014
Rak functions as a tumor suppressor by regulating PTEN protein stability and function.
Yim EK et al.
Cancer Cell, 2009
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
Koul D et al.
Oncogene, 2002
Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication.
Taylor B et al.
Neuro-oncology Advances, 0
Select a paper to view details